Bio-Rad Laboratories, a leader in life science research and clinical diagnostics, has expanded its Pioneer™ Antibody Discovery Platform to include the fast generation and screening of bispecific antibodies using the proprietary SpyLock Technology. This enhancement allows researchers to quickly identify effective antibody combinations for further development, bolstering the platform's ability to deliver high-quality antibody candidates swiftly.
The Pioneer Platform, with its extensive library of 225 billion unique Fab antibodies and the SpyDisplay technology, offers customizable discovery services tailored to diverse project needs. Notably, Bio-Rad's Pioneer Platform is already making an impact globally in areas like immuno-oncology and infectious diseases. A collaboration with Salipro Biotech has led to the discovery of novel human antibodies with potential for improved efficacy in challenging therapeutic targets.
John Cardone, Marketing Manager of Custom Antibodies at Bio-Rad, highlights the significance of this expansion, noting that the new SpyLock service further strengthens Bio-Rad's commitment to supporting researchers with advanced tools for bispecific antibody screening, enabling faster progress in therapeutic development.
This article is a summary of a published press release
